Latest Information Update: 07 Jul 2016
At a glance
- Originator Kadmon Gene Therapy Holdings
- Developer Kadmon Gene Therapy Holdings; National Institute of Dental and Craniofacial Research
- Class Gene therapies
- Mechanism of Action Gene transference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Xerostomia
Most Recent Events
- 01 Apr 2015 Phase-I/II clinical trials in Xerostomia in USA (unspecified route)